Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandro Michael Hasenhütl has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful Endoscopic Management of Bouveret Syndrome by Transpyloric Stone Relocation and Intragastric Mechanical Lithotripsy

    by Mohamed El-Mahrouk, Emina Talakić, Robert Sucher, Sandro M. Hasenhütl

    Background: Bouveret syndrome is a rare form of gallstone ileus in which a gallstone migrates through a bilioenteric fistula and impacts at the gastric outlet or proximal duodenum. It affects predominantly frail elderly women, in whom an endoscopy-first strategy is desirable; however, complete endoscopic clearance is achieved in fewer than half of cases and becomes markedly less likely as stone size increases, meaning that large stones often prompt surgery. Case Presentation: A 95-year-old woman presented with four days of vomiting and obstipation. Computed tomography demonstrated gastric outlet obstruction caused by a large gallstone impacted in the duodenal bulb with pneumobilia, consistent with Bouveret syndrome. Owing to her advanced age and operative risk, an entirely endoscopic approach was pursued. Initial extraction within the duodenal bulb using a retrieval net and foreign-body forceps failed because neither device could engage the stone. The closed forceps were therefore used as a lever to rotate and mobilize the stone until complete capture with the retrieval net became possible, after which the 37 mm stone was relocated through the pylorus into the stomach under controlled traction. As intact transoral extraction remained impossible, intragastric mechanical lithotripsy was performed and all fragments were retrieved transorally, achieving complete endoscopic clearance without surgery. The post-procedural course was uneventful; oral intake was resumed the following day, and the patient was discharged in good condition. Conclusions: Relocation of an impacted gallstone into the stomach before mechanical lithotripsy has been described previously. In this case, the stone could not initially be engaged; closed forceps used as a lever to rotate and mobilize it made capture with a retrieval net, and thus relocation, possible. This step allowed for complete endoscopic clearance without surgery in this single high-risk patient; its wider applicability remains to be established.

  • Open Access

    Microbiome-Targeted Modulation in Renal Transplantation

    by Hans Michael Hau, Nora Jahn, Robert Karitnig, Sandro Michael Hasenhütl, Robert Sucher, Philipp Stiegler, Sven Laudi

    The gut microbiome has emerged as a critical determinant of health and disease across virtually all organ systems. In the context of chronic kidney disease (CKD) and renal transplantation, mounting evidence reveals a complex bidirectional relationship between the intestinal microbiota and kidney function—commonly referred to as the gut–kidney axis. Patients with CKD harbor a profoundly altered gut microbial ecosystem characterized by reduced diversity, depletion of beneficial commensal organisms, and expansion of pathobiont taxa capable of generating uremic toxins and pro-inflammatory mediators. These perturbations are further compounded by the uremic milieu itself, dietary restrictions, frequent antibiotic exposure, and the use of immunosuppressive agents following transplantation. The gut–liver–kidney axis adds an additional layer of complexity, linking hepatic metabolism, bile acid signaling, endotoxemia, and systemic immune activation to the progression of renal disease. Gut-derived metabolites—including short-chain fatty acids (SCFAs), bile acids, trimethylamine N-oxide (TMAO), and tryptophan-derived uremic solutes such as indoxyl sulfate and p-cresyl sulfate—serve as molecular mediators of inter-organ crosstalk and have been identified as both biomarkers and therapeutic targets. A growing body of literature supports the diagnostic and prognostic utility of microbiome composition and its metabolic signatures in patients with CKD and those undergoing renal replacement therapy. Therapeutic strategies aimed at restoring microbial homeostasis—encompassing dietary interventions, prebiotics, probiotics, synbiotics, fecal microbiota transplantation (FMT), bile acid–based therapies, and novel pharmacological approaches—hold considerable promise for improving outcomes in CKD and transplant recipients. Importantly, the bidirectional relationship between immunosuppressive drugs and the gut microbiota has emerged as a clinically significant determinant of both microbial ecology and drug pharmacokinetics: each major immunosuppressive agent class—corticosteroids, calcineurin inhibitors, mycophenolate mofetil, and mTOR inhibitors—induces characteristic dysbiotic patterns, while in turn, the microbiota modulates drug bioavailability through enzymatic biotransformation (notably bacterial beta-glucuronidase activity affecting mycophenolic acid enterohepatic recirculation) and modulation of host drug-metabolizing enzymes. This narrative review provides a comprehensive overview of the current understanding of microbiome dysbiosis in the setting of renal disease and transplantation, examines the mechanistic underpinnings of the gut–liver–kidney axis, details the multifaceted impact of dysbiosis on transplant outcomes—including allograft function and rejection, infection, post-transplant diabetes, and cardiovascular complications—and critically appraises the translational potential of microbiome-targeted interventions. We conclude by highlighting ongoing challenges and future directions toward personalized, microbiome-informed clinical care.